A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
Status:
SUSPENDED
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults.
Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.